Navigation Links
Sales of Antiretroviral Drugs for HIV Will Decrease Marginally Over the Next Decade, from an Estimated $13.4 Billion in 2012 to $13.1 Billion in 2022
Date:12/4/2013

BURLINGTON, Mass., Dec. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that major-market sales of antiretroviral (ARV) drugs for HIV will decrease marginally over the next decade, from an estimated $13.4 billion in 2012 to $13.1 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Human Immunodeficiency Virus (HIV) finds that the strongest factor constraining the HIV therapy market is the generic erosion of numerous key ARV drugs, such as efavirenz (Bristol-Myers Squibb's Sustiva, Merck/Banyu's Stocrin), tenofovir disoproxil fumarate [TDF] (Gilead/Japan Tobacco's Viread), atazanavir (Bristol-Myers Squibb's Reyataz), darunavir (Janssen's Prezista), emtricitabine/TDF (Gilead/Japan Tobacco's Truvada) and efavirenz/emtricitabine/TDF (Gilead/ Bristol-Myers Squibb's Atripla). Increasing availability of generics in cost-constrained markets will inhibit uptake of new, higher-priced agents and is responsible for decreased ARV sales in major pharmaceutical markets, particularly European markets where the impact of generic erosion will be the heaviest. Notably, all three active pharmaceutical agents in the 2012 sales leader, Gilead/ Bristol-Myers Squibb's single-tablet regimen (STR) Atripla will lose patent protection during the 2012 to 2022 forecast period, paving the way for generic STR prescribing in the major markets.

A key driver of sales growth in the HIV market is the increasing uptake of new, premium-priced agents, including integrase inhibitors and integrase inhibitor-based STRs. Diagnosis will also increase owing to broadening screening efforts and an expansion of the treatment-eligible population as a result of treatment guidelines urging treatment for HIV patients irrespective of CD4 cell levels, particularly in the United States.

The findings also reveal that, of the emerging therapies, the recently launched integrase inhibitor dolutegravir (ViiV's Tivicay) is best poised for commercial success during the 2012-2022 forecast period. ViiV is already marketing dolutegravir as a stand-alone product that can be used with different NRTI backbone regimens in the United States and has submitted regulatory filings to the EMA to support this usage.

"Uptake of dolutegravir will be somewhat constrained by the availability of generics for heavily prescribed, currently marketed ARV drugs such as Atripla and Gilead's newly available integrase inhibitor- based STR Stribild," said Decision Resources Analyst Seamus Levine-Wilkinson, Ph.D. "Nevertheless, dolutegravir's strong clinical profile will enable this agent to achieve blockbuster status as both a stand-alone agent and as a component of the recently filed 572-Trii STR."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
2. InspireMD Appoints Rick Olson as Vice President of Global Sales Operations
3. Radiation Therapy Equipment - Global Strategic Business Report 2012-2018 - Replacement Sales Spur Global Radiotherapy Market
4. Technology & Innovation Transforming Pharmaceutical Sales Training Programs
5. TCS Named a Global Leader in IDC MarketScape: Worldwide Life Science Sales & Marketing ITO 2013 Vendor Assessment by IDC Health Insights
6. Alpinion Medical Systems Appoints Lyle Mussman to Lead U.S. Ultrasound Sales
7. Richard Wolf USA And MAQUET Launch OR Integration Sales Partnership
8. Beat the Rush & Avoid the Crowds with CVS/pharmacy Black Friday Sales Event
9. Absorption Pharmaceuticals Expands Sales and Service Team to Answer Physicians Growing Demand for Promescent
10. Creekridge Capital Grows Healthcare Sales Team
11. Skyline Medical Appoints Stephen Zastrow as Senior Vice President of Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... February 11, 2016 ,   ... EUR 1,377.2m  Adjusted EBITDA climbs to EUR 277.9m   ... 3.41  Proposed dividend of EUR 0.85 per share (2014: ... tubing business and refinancing successfully completed  Approximately 9% ... organic basis  Adjusted EBITDA expected for 2016 at ...
(Date:2/10/2016)... DALLAS , Feb. 10, 2016  Fotona, based in ... it will launch its new ST PRO Lightwalker dental laser ... Chicago Dental Society from 25-27 February, 2016 in booth #4815. ... tissue dental laser with many of the features of the ... $49,900, the ST PRO competitive price will be very attractive ...
(Date:2/10/2016)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today announced ... full year ended December 31, 2015. ... year for Vanda with the continued growth of HETLIOZ ... HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., Vanda,s ... U.S. product portfolio builds on this success and underscores ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Dickinson Insurance & Financial Services continues their commitment ... in support of a local boy named Barrett, who has been fighting ALL leukemia ... and rally support for, all local families dealing with childhood cancer. Information on how ...
(Date:2/11/2016)... , ... February 11, 2016 , ... Be Well ... office in the heart of Old Town at 108 South Columbus St, Suite 201, ... the highest level of medical care in the convenience of their homes, offices or ...
(Date:2/11/2016)... ... 11, 2016 , ... Husted Kicking has completed its Third Annual ... 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event serves ... NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization to ...
(Date:2/11/2016)... ... February 11, 2016 , ... Research led ... rates of several common cancer screenings, especially among women. Cancer screenings are often ... rates. , The study,“What Does Medicaid Expansion Mean for Cancer Screening and ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... as the World Molecular Imaging Congress (WMIC), will be held in New York ... meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging ...
Breaking Medicine News(10 mins):